ABSTRACT
PURPOSE: Chromium treatment has been shown to improve glucose regulation in some populations. The purpose of this study was to evaluate whether chromium picolinate (CrPic) supplementation improves glucose regulation in overweight individuals with binge-eating disorder (BED). METHODS: In this double-blinded randomized pilot trial, participants (N = 24) were randomized to high (HIGH, 1000 mcg/day, n = 8) or moderate (MOD, 600 mcg/day, n = 9) dose of CrPic or placebo (PL, n = 7) for 6 months. Participants completed an oral glucose tolerance test (OGTT) at baseline, 3 months, and 6 months. Fixed effects models were used to estimate mean change in glucose area under the curve (AUC), insulinAUC, and insulin sensitivity index (ISI). RESULTS: Results revealed a significant group and time interaction (p < 0.04) for glucoseAUC, with glucoseAUC increasing significantly in the PL group (p < 0.02) but decreasing significantly in the MOD group (p < 0.03) at 6 months. InsulinAUC increased significantly over time (main effect, p < 0.02), whereas ISI decreased significantly over time (main effect, p < 0.03). CONCLUSION: As anticipated, a moderate dose of CrPic was associated with improved glycemic control, whereas PL was associated with decreased glycemic control. It was unexpected that the improved glycemic control seen in the MOD dose group was not seen in the HIGH dose group. However, although participants randomized to the HIGH dose group did not have improved glycemic control, they had better glycemic control than participants randomized to the PL group. These findings support the need for larger trials.
Subject(s)
Binge-Eating Disorder/drug therapy , Hypoglycemic Agents/therapeutic use , Overweight/drug therapy , Picolinic Acids/administration & dosage , Picolinic Acids/therapeutic use , Adult , Binge-Eating Disorder/blood , Binge-Eating Disorder/complications , Blood Glucose/analysis , Blood Glucose/drug effects , Dose-Response Relationship, Drug , Double-Blind Method , Female , Glucose Tolerance Test , Humans , Hypoglycemic Agents/administration & dosage , Insulin/blood , Insulin Resistance , Male , Middle Aged , Overweight/blood , Overweight/psychology , Pilot Projects , Time FactorsABSTRACT
(Reprinted from the Journal of the American Academy of Child & Adolescent Psychiatry 2015;54(5):412-425 with permission from the Academy).
ABSTRACT
This Practice Parameter reviews evidence-based practices for the evaluation and treatment of eating disorders in children and adolescents. Where empirical support is limited, clinical consensus opinion is used to supplement systematic data review. The Parameter focuses on the phenomenology of eating disorders, comorbidity of eating disorders with other psychiatric and medical disorders, and treatment in children and adolescents. Because the database related to eating disorders in younger patients is limited, relevant literature drawn from adult studies is included in the discussion.
